DENVER — SeaStar Medical Holding Corporation (Nasdaq: ICU) announced today that new data from its post-approval SAVE Registry will be unveiled at the American Society of Nephrology (ASN) Kidney Week 2026. The late-breaking abstract, which highlights the clinical performance of the company’s pediatric therapy, has been accepted for a featured poster presentation in Denver, Colorado.
The presentation, titled “Improved Outcomes in Pediatric Sepsis-Associated (SA) AKI: Comparison of the Selective Cytopheretic Device for Pediatrics (SCD-PED) Surveillance Registry (SAVE) with a Historical Cohort,” is scheduled for October 22, 2026. The findings will be shared at the Colorado Convention Center by a team of prominent medical experts, including lead author Dr. Nathan L. Kleinman and several other specialists in pediatric critical care and nephrology.
SeaStar Medical’s flagship product, QUELIMMUNE (SCD-PED), received FDA approval in 2024. It remains the only therapy specifically authorized for treating life-threatening Acute Kidney Injury (AKI) caused by sepsis or septic conditions in critically ill children who require renal replacement therapy. The SAVE Registry was established to track real-world clinical outcomes for patients receiving this treatment, providing essential data on the device’s effectiveness outside of a controlled trial environment.
The upcoming presentation at ASN Kidney Week is highly anticipated by the medical community, as it offers a direct comparison between patients treated with the SCD-PED and a historical cohort of patients who did not have access to the technology. Such data is critical for validating the therapeutic impact of the device in managing one of the most challenging conditions in pediatric intensive care.
“This acceptance for a late-breaking presentation at such a prestigious forum underscores the clinical significance of the SAVE Registry,” noted representatives from SeaStar Medical.
Beyond its pediatric applications, SeaStar Medical is actively expanding the reach of its Selective Cytopheretic Device (SCD) technology. The company has secured FDA Breakthrough Device Designation for six distinct therapeutic indications, accelerating its path toward potential future approvals. Currently, the company is conducting the NEUTRALIZE-AKI pivotal clinical trial, which investigates the efficacy of SCD therapy in adults with AKI requiring continuous renal replacement therapy. With over 200,000 adult patients in the United States affected by this condition annually, the trial represents a significant expansion effort for the company.
The poster session (Abstract #TH-PO1291) will take place in Exhibit Hall A of the Colorado Convention Center between 10:00 a.m. and 12:00 p.m. MT. As SeaStar Medical continues its mission to provide transformational treatments for those facing organ failure, the data presented in Denver will likely serve as a cornerstone for discussions regarding the future of sepsis-associated AKI care.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
